Neurocrine Biosciences Inc.’s (NASDAQ:NBIX) ERUDITE phase two clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in schizophrenia patients.
It failed to replicate the cognitive endpoint data seen in the earlier INTERACT study due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms.
Also Read: Neurocrine Biosciences’ Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
In the INTERACT study, 50 mg luvadaxistat resulted in a statistically significant improvement in the measure of cognition on the Brief Assessment of Cognition in Schizophrenia (BACS) and cognitive performance on the Schizophrenia ...
